Navigation Links
United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
Date:2/15/2011

he quarter ended December 31, 2010 increased by $57.6 million when compared to the quarter ended December 31, 2009. The growth in revenues is predominately from the increase in the number of patients being prescribed our products. In addition, sales of Remodulin increased by approximately $9.2 million as the result of price increases that went into effect during 2010. Gross margin from sales for the quarters ended December 31, 2010 and 2009 were $146.0 million and $95.1 million, respectively, or 88% of total revenue for both of these quarters. These trends were consistent with the results for the years ended December 31, 2010 and December 31, 2009.

The table below summarizes the components of revenues (in thousands):Three Months EndedDecember 31,Year EndedDecember 31,2010200920102009Cardiopulmonary products:Remodulin

$

101,879$

86,415$

403,599$

331,579Tyvaso

48,71415,155151,79720,268Adcirca

12,8044,27536,3075,789Telemedicine products and services

2,7872,79510,93210,968License fees

2932831,1961,244Total revenues

$

166,477$

108,923$

603,831$

369,848Operating Expenses. Our operating expenses consist of research and development, selling, general and administrative, and costs of service and product sales.

The table below summarizes research and development expense by major project and non-project components (in thousands):Three Months EndedDecember 31,Year EndedDecember 31,2010200920102009Project and non-project:Cardiopulmonary

$

31,908$

22,906$

86,161$

61,574Share-based compensation

19,77411,12945,87836,294Other

10,5736,99734,72224,320Total research and development expense

$

62,255$

41,032$

166,761$

122,188Cardiopulmonary.  The increase in cardiopulmonary project expenses of
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
2. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
3. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
4. United Therapeutics to Announce Third Quarter 2008 Financial Results Before Market Open on Thursday, October 30, 2008
5. International Drug & Explosive Detection Firm Identa Corp Releasing: Jant Pharmacal Corporation Reports Successful Market Penetration of the Accutest(R) IDenta Co-brand in the United States and Oversees
6. Lilly Announces Launch of Color Differentiation System for Humalog(R) and Humulin(R) U-100 Insulin Products in the United States
7. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
8. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
9. United Therapeutics Reports Third Quarter 2008 Financial Results
10. Lilly Contributes $11.1 Million to United Way Annual Campaign
11. First United Kingdom Patients Treated With Percutaneous MitraClip(R) System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)...  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW ... for cancer, announced today that Dr. Marnix L. ... be making an Industry Expert Theater Presentation at the ... on Saturday, May 30, 2015, from 3 to ... McCormick Place. Dr. Bosch will provide an ...
(Date:5/27/2015)... , May 27, 2015  RXi Pharmaceuticals Corporation ... on discovering and developing innovative therapies primarily in ... update on the status of the Company,s Series ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... and 21 shares of Series A Preferred Stock ...
(Date:5/26/2015)... Regenestem Network has announced the grand ... Aires, Argentina. The clinic will be lead by Silvina ... assembled a multidisciplinary team of medical professionals who specialize ... Madero office. , The new Regenestem Network members ... studies in cellular therapies, and establish Regenestem protocols to ...
(Date:5/26/2015)... CITY, California and HILDEN, ... QIAGEN N.V. (NASDAQ: QGEN ; ... launch of its QIAGEN Clinical Insight ® ... testing labs to interpret and report on genomic ... two supported applications for the bioinformatics platform are ...
Breaking Biology Technology:NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5
... NeoStem Shareholders, We would like to take a ... for NeoStem (NYSE Amex: NBS ) – and to ... the company forward in 2012 and beyond. , We have ... LLC ("Amorcyte"). , We believe our therapeutic product development team ...
... LA JOLLA, Calif., Jan. 2, 2012 Renowned biochemist ... and CEO of The Scripps Research Institute January 1, ... for more than two decades. (Photo:  ... opportunity to advance the institute,s mission, creating knowledge in ...
... Dec. 28, 2011  MiMedx Group, Inc. (OTCBB: MDXG), ... protected regenerative biomaterials and bioimplants processed from human ... private placement offering to sell convertible notes and ... the offering, which commenced on October 15, 2011, ...
Cached Biology Technology:NeoStem's CEO Letter to Shareholders 2NeoStem's CEO Letter to Shareholders 3NeoStem's CEO Letter to Shareholders 4Michael A. Marletta Takes Office as New President of Scripps Research Institute 2MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3
(Date:5/8/2015)... 8, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... members of the executive management team will present at the ... Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company Technology, ... ET Location: The New York Palace Hotel, New ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
(Date:4/27/2015)... ATLANTA , April 27, 2015  For more ... and trade show has been the premier worldwide event ... Systems 2015 is a must-attend event for any local, ... insight into the emerging commercial markets and current applications ... and innovations of this projected $48 billion industry, and ...
Breaking Biology News(10 mins):Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... may be onto an ocean of discovery because of his ... The research is likely to lead to making ceramics ... armour many times stronger. These findings were published in ... and focused on the mantis shrimp,s ability to shatter aquarium ...
... within the next five years and in ten years from ... today: what we are going to see at ESMO 2012 ... technologies can improve the tailoring of cancer therapies for the ... President More than 17,000 participants from over 120 different ...
... /PRNewswire-iReach/ -- FirstMark, the diagnostic division of ... Shah has joined its Scientific Advisory Board. ... Director of the Division of Cardiology. He also is ... Cedars-Sinai Medical Center where he leads several studies that ...
Cached Biology News:NTU researchers study little mighty creature for scientific breakthrough 2NTU researchers study little mighty creature for scientific breakthrough 3ESMO 2012 Congress: A path for medical oncology innovations 2ESMO 2012 Congress: A path for medical oncology innovations 3ESMO 2012 Congress: A path for medical oncology innovations 4FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board 2FirstMark Welcomes Renowned Cardiologist and Researcher Dr. Prediman K. Shah to Scientific Advisory Board 3
Lysozyme C (W-20)...
... Blood bank refrigerators: ,Each upright model ... superior 4C temperature uniformity for refrigerated blood. ... 2000 Surveillance Module for complete blood storage ... are equipped with the HemaPro 101 alarm/monitor. ...
... RNase H- Reverse Transcriptase ... version of SuperScript™ II ... SuperScript™ II it synthesizes ... from single-stranded RNA DNA ...
Vapor phase risers are available in various heights to accomodate a variety of inventory solutions. Risers are used to creat a false bottom in which the tanks platform rests and Liquid nitrogen is s...
Biology Products: